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ABSTRACT: Reporters secreted into the conditioned medium of cells in
culture or into blood in vivo have shown to be useful tools for simple and
noninvasive monitoring of biological processes in real-time. Here, we
characterize the naturally secreted Vargula luciferase as a secreted blood
reporter and show that this reporter can be multiplexed with the secreted
Gaussia luciferase and alkaline phosphatase for simultaneous monitoring of
three diﬀerent cellular processes in the same biological system. We applied
this system to monitor the response of three diﬀerent subsets of glioma
cells to a clinically relevant chemotherapeutic agent in the same well in
culture or animal in vivo. This system could be extended to any ﬁeld to
detect multiple processes in the same biological system and is amenable
for high-throughput screening to ﬁnd drugs that aﬀect multiple cellular
populations/phenomena simultaneously.
Reporters secreted in blood are valuable tools for sensitiveand fast detection, quantiﬁcation, and noninvasive ex vivo
monitoring of biological processes in in vivo models.1
Currently, the three most commonly used blood reporters
are the secreted embryonic alkaline phosphatase (SEAP),2−5
soluble peptides derived from human carcioembryonic antigen
(hCEA) and human chorionic gonadotropin (βhCG),6−9 and
Gaussia luciferase (Gluc).10−14 The level of these secreted
reporters can be measured over time in blood, serum, and urine
to generate multiple data sets without the need to sacriﬁce the
animal, since only a small amount of ﬂuid is required. In
contrast to other tools for monitoring of cellular processes,
secreted blood reporters are suitable to follow biological
parameters in the course of time, providing new insights in the
factors contributing to disease development and progression.1
During the last two decades, secreted blood reporters have
proven their value in a wide variety of medical ﬁelds including
the study of embryo development, viral dissemination, the fate
of (stem) cells, gene transfer, tumorigenesis, and response to
therapy.14−16 The contribution of secreted blood reporters to
understanding of these complicated processes would increase
even further, if instead of one, multiple parameters could be
measured simultaneously and over time.
The discovery of new secreted reporters with diﬀerent
substrate speciﬁcities, emission spectra, and detection assays
will allow the development of multiplex assays that are capable
in simultaneously monitoring several processes, given that their
separate reactions remain distinguishable. Here, we charac-
terized the naturally secreted luciferase from the marine
ostracod Vargula (Cypridina) hilgendorf i (Vluc)17,18 as a
blood reporter and multiplexed it with Gluc and SEAP to
develop a triple blood reporter system to monitor three distinct
biological processes. As a proof of concept, we successfully
monitored the response of three diﬀerent subsets of glioma
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cells to the chemotherapeutic agent temozolomide19 in the
same animal. This multiplex system can be extended and
applied to many diﬀerent ﬁelds for simultaneous monitoring of
multiple parameters in the same biological system.
■ EXPERIMENTAL SECTION
Lentivirus Vectors. Lentivirus vectors expressing CMV-
SEAP, CMV-Gluc, and CMV-Fluc were previously described.14
Codon-optimized Vluc cDNA for mammalian gene expression
was ampliﬁed by polymerase chain reaction (PCR) from
pCMV-Vluc (targeting systems) and cloned in a similar vector
backbone as CMV-SEAP creating CMV-Vluc. Lentivirus
vectors were packaged as previously described.14
Cell Culture and Reagents. U87 human glioma cells were
obtained from ATCC. U87R1 and U87R2 cells were generated
by long-term exposure (twice per week over 7 weeks) of U87
parental cells (in duplicates) with a clinically relevant
concentration of Temozolomide (TMZ; 100 μM). Resistant
cells in culture were regularly challenged with 100 μM TMZ to
maintain the resistant phenotype. All cells were grown in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum (Sigma, St. Louis, MO, U.S.A.),
100 U penicillin, and 0.1 mg streptomycin (Sigma) per
milliliter, at 37 °C and 5% CO2 in a humidiﬁed atmosphere.
Temozolomide was obtained from Sigma.
Reporter Substrates. Coelenterazine was obtained from
NanoLight Technology (Pinetop, AZ) and resuspended at 5
mg/mL in acidiﬁed methanol. Vargulin substrate was obtained
from NanoLight Technology and was resuspended at 5 mg/mL
in acidiﬁed methanol. D-luciferin was purchased from Gold
Biotechnology (St. Louis, MO) and resuspended at 25 mg/mL
in PBS. SEAP was detected using the Great EscAPe SEAP kit
(Clontech) as per manufacturer’s instructions.
In Vitro Experiments. Seven thousands of either U87-
Gluc, U87R1-Vluc, or U87R2-SEAP/Fluc cells (for singleplex
assay) or a combination of all three cells (2500 of each line for
multiplex) were plated in a 96-well plate in a total volume of
100 μL. Twenty-four hours later, cells were treated with either
Temozolomide (100 μM) or DMSO vehicle. At diﬀerent time
points, 10 μL aliquots (in triplicates) of cell-free conditioned
medium was collected and assayed for either Gluc, Vluc, or
SEAP using either coelenterazine (5 μg/mL in PBS), vargulin
(0.25 μg/mL in PBS), or the Great EscAPe SEAP, respectively.
We refreshed the media of cells 6 h before each measurement
to avoid accumulation of the reporter.
Animal Studies and Blood Collection. All animal studies
were approved by the Massachusetts General Hospital Review
Board. U87 human glioma cells, U87R1 and U87R2, were
transduced with each lentivirus vector for stable expression by
adding the vector directly to the cells using 10 transducing units
of each vector per cell leading to >90% transduction eﬃciency.
To generate subcutaneous tumors, diﬀerent amount of these
cells (in 50 μL) were mixed with equal volume of Matrigel and
injected in the ﬂanks of athymic nude mice. For brain tumor
model, a mixture of these cells (25 000 per cell line, in 2 μL of
Opti-MEM) was intracranially injected in the left midstriatum
Figure 1. Triple secreted reporter system. (a) Linearity of Vluc blood reporter with respect to cell number. Diﬀerent U87 glioma cells expressing
Vluc were implanted subcutaneously in nude mice (n = 4/group). One week later, 5 μL of blood or urine (in triplicates) was assayed for Vluc activity
using 100 μL of the vargulin substrate. (b) half-life of Vluc in circulation. Conditioned medium from U87 cells expressing Vluc were ﬁltered, and 150
μL was i.v. injected in nude mice (n = 4). At diﬀerent time points, 5 μL blood (in triplicates) were assayed for Vluc activity. (c) Speciﬁcity of each
secreted reporter for its substrate. Mice were injected subcutaneously with U87 cells expressing either Gluc, Vluc or SEAP (n = 4/group). Three days
later, 5 μL blood or serum (in triplicates) was assayed for Gluc, Vluc, and SEAP activity. A signiﬁcant signal is obtained in blood/serum only with the
proper reporter/substrate combination.
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of nude mice using the following coordinates from bregma in
mm: anterior-posterior +0.5, medio-lateral +2.0, dorso-ventral
−2.5. These injections were performed using a Micro 4
Microsyringe Pump Controller (World Precision Instruments,
Sarasota, FL) attached to a Hamilton syringe with a 33-gauge
needle (Hamilton, Rena, NV) at a rate of 0.2 μL/min. One
week later, mice were randomized in 2 groups (n = 6/group)
and treated with either 10 mg/kg temozolomide or DMSO
vehicle. Blood samples were collected from these mice, as well
as from mice without tumors (negative control), by making a
small incision in the tail and directly adding it to an eppendorf
tube containing EDTA as an anticoagulant (10 mM ﬁnal
concentration).
Ex Vivo Multiplex Blood Reporter Assays. For Gluc
assay, activity was measured by injecting 100 μL of 100 μM
coelenterazine (Nanolight, Pinetop, AZ) to 5 μL of blood and
acquiring photon counts over 10 s using a luminometer
(Dynex). The SEAP chemiluminescence activity was measured
in 5 μL serum using the Great EscAPe SEAP kit (Clontech) as
per manufacturer’s instructions. For Vluc assay, activity was
measured in 5 μL blood or serum after injecting 100 μL 0.25
μg/mL of vargulin (diluted in PBS) and acquiring photon
counts for 10 s using a luminometer.
Triple in Vivo Imaging. For Fluc imaging, mice were
injected i.p. with 200 mg/kg body weight of D-luciferin solution
and imaging was performed 10 min later. For Gluc imaging,
mice were injected i.v. (via retro-orbital route) with 5 mg/kg
body weight of coelenterazine solution diluted in PBS and
imaging was performed immediately. For Vluc in vivo imaging,
mice were injected i.v. with 4 mg/kg body weight (diluted in
PBS) and imaging was performed immediately. For sequential
imaging of all three reporters, we imaged Gluc ﬁrst followed by
Vluc 4 h later and Fluc on the following day to allow enough
time for the signal to reach background levels between diﬀerent
imaging sessions. Imaging was performed using an IVIS
Spectrum optical imaging system ﬁtted with an XGI-8 Gas
Anesthesia System (Caliper Life Sciences, Hopkinton, MA).
Bioluminescent images were acquired using the autoexposure
function. Data analysis for signal intensities and image
comparisons were performed using Living Image software
(Caliper Life Sciences). To calculate radiance for each animal,
regions of interest (ROIs) were carefully drawn around each
signal in the brain which is expressed as radiance (photons/s/
cm2/steradian).
■ RESULTS AND DISCUSSION
We ﬁrst characterized a codon-optimized Vluc variant for
mammalian gene expression as a blood reporter. Diﬀerent
amounts of U87 human glioma cells stably expressing Vluc
were implanted subcutaneously in nude mice. Three days
postimplantation, 5 μL blood samples (in triplicates) were
withdrawn, mixed with EDTA (as an anticoagulant), and
assayed for Vluc activity using a luminometer after addition of
the vargulin substrate. Several optimization steps for the
detection of Vluc in the blood were ﬁrst performed using
diﬀerent concentrations of the vargulin substrate in blood and
serum. We found that 100 μL of 0.25 μg/mL vargulin (diluted
in PBS) gave the best signal-to-background (S/B) ratio
(Supporting Information Figure 1a). Since hemoglobin in
whole blood is known to interfere with bioluminescence, we
compared the activity of Vluc in blood versus serum and
observed that serum gave higher S/B ratio at a concentration of
0.25 μg/mL vargulin (Supporting Information Figure 1a).
EDTA anticoagulant did not have any eﬀect on the Vluc
activity (Supporting Information Figure 1b). Using these
optimized conditions, we observed that Vluc activity in blood
is linear with respect to cell number in a range covering at least
3 orders of magnitudes (Figure 1a). We then checked the
possibility of detecting Vluc in urine, similar to Gluc.13,14 We
found that Vluc activity in urine was also linear with respect to
cell number, albeit less sensitive, showing that Vluc is cleared by
the kidneys (Figure 1a). We next evaluated the half-life of Vluc
in circulation by intravenously injecting Vluc-containing
conditioned medium of cells in nude mice and assaying
blood for Vluc activity at diﬀerent time points. We found that
the Vluc half-life in circulation to be around 3 h (Figure 1b),
similar to previously reported SEAP.4 Gluc on the other hand
has a very short half-life of 20 min.14 This relatively fast
clearance of these reporters allow them to be used as markers
for dynamic events.
Since it is of utmost importance that the chemical reaction of
the individual reporters used for multiplex application can be
distinguished, we determined the speciﬁcity of each reporter to
its substrate in the blood. U87 glioma cells stably expressing
Gluc, Vluc, or SEAP (all under the control of CMV promoter)
were implanted subcutaneously in diﬀerent nude mice. Three
days later, 5 μL blood was assayed for each reporter activity
using coelenterazine, vargulin or SEAP substrate. Signiﬁcant
signal from blood was obtained only when the proper reporter/
substrate combination was used, showing no substrate overlap
or cross reaction among the diﬀerent reporters, and indicating
that Gluc, Vluc, and SEAP can be used together for multiplex
applications (Figure 1c).
Finally, we applied the triple reporter system for noninvasive
monitoring of three diﬀerent subsets of U87 glioma cells in
response to temozolomide (TMZ), the chemotherapeutic agent
of choice for the treatment of grade IV glioma.19 We used U87
parent cells as well as two TMZ-resistant subclones of these
cells, U87R1 and U87R2 (Supporting Information Figure 2).
We ﬁrst conﬁrmed that each of the three reporters (Gluc, Vluc
and SEAP) could be used to monitor cell viability. U87 parent
cells (sensitive to TMZ) were transduced with a lentivirus
vector to express either Gluc, Vluc or SEAP. These cells were
plated in a 96-well plate and treated with either DMSO or 100
μM TMZ. At diﬀerent time points, aliquots of conditioned
medium were assayed for each reporter activity. A substantial
diﬀerences between TMZ-treated and control samples was
observed with all three reporters conﬁrming that Gluc, Vluc
and SEAP can be used as markers for cell viability
(Supplementary Figure 3). We then applied the triple reporter
for multiplex applications. U87 parent cells were engineered by
a lentivirus vector to express Gluc (U87-Gluc), while U87R1
were engineered to express Vluc (U87R1-Vluc) and U87R2 to
express both SEAP and Fluc (U87R2-SEAP/Fluc). Fluc here is
used for in vivo localization of U87R2 cells with bio-
luminescence imaging (since SEAP reporter cannot be imaged
in vivo), while Gluc and Vluc are used to localize U87 and
U87R1 cells respectively. First, the triple secreted reporter
system was conﬁrmed in culture by plating 7000 cells of U87-
Gluc, U87R1-Vluc, U87R2-SEAP/Fluc (singleplex), or a
combination of all three cells (2500 of each line; multiplex)
in a 96-well plate. The next day, cells were treated with TMZ
(100 μM) or DMSO control. Aliquots of the conditioned
medium were then assayed for each luciferase activity every day
over 4 days. Using the singleplex assay, we observed that U87-
Gluc cells responded very well to TMZ (>50% cell death),
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while this drug had no signiﬁcant eﬀect on U87R1-Vluc and
U87-R2-SEAP/Fluc as expected (Figure 2). The multiplex
assay showed the exact same phenomena proving that these
three reporters can be used together for simultaneous
monitoring of three distinct biological processes over time.
We then mixed these three cell lines equally and intracranially
implanted 75 000 cells (25 000 of each line) in the brain of
nude mice. One week later (time zero), a sample of blood was
withdrawn and a group of mice (n = 6) was injected with 10
mg/kg TMZ, while the other group (n = 6) was injected with
DMSO vehicle (control). Blood was collected at diﬀerent time
points and 5 μL of blood (for Gluc) or serum (for Vluc and
SEAP) in triplicates was assayed for each reporter activity using
coelenterazine, vargulin or SEAP assay respectively. As
expected, a continuous decrease in Gluc level in the blood in
response of parental U87 cells to TMZ was observed over time
in the treated group, while an increase in Gluc signal was
observed in the control group (Figure 3). On the other hand,
both Vluc and SEAP levels increased in serum over time in
both treated and control groups showing that U87R1 and
U87R2 cells are resistant to TMZ (Figure 3). Before (day zero)
and 10 days post-treatment, mice were imaged for Gluc, Vluc,
and Fluc after injection of coelenterazine, vargulin, and D-
luciferin conﬁrming the blood assays data (Figure 3). Gluc
imaging was performed ﬁrst followed by Vluc imaging (4 h
later) and then Fluc imaging 24 h later. This sequential imaging
ensured that the signal of the ﬁrst reporter reached background
level before imaging the second reporter (Supporting
Information Figure 4). All together, these results show that
Gluc, Vluc, and SEAP can be multiplexed together as blood
reporters for noninvasive monitoring of biological processes, in
real time.
Luciferase-mediated bioluminescence imaging is widely used
as a reporting tool for monitoring various biological processes
in vitro and in vivo. In vivo bioluminescence imaging has
several disadvantages including photon absorption by tissues as
a function of depth and the ineﬃciency of luciferase substrates
in crossing the blood−brain/tumor barrier. Further, it is time-
consuming and involves some inconvenience due to frequent
anesthesia, need for transport of animals, and repeated systemic
substrate injections, thereby limiting the ability to monitor
relatively large cohorts in small time intervals. In addition,
certain biological processes cannot be eﬃciently measured
using in vivo bioluminescence imaging because of dispersion of
the bioluminescence signal throughout the animal or simply
because the signal is below the detection limit of the CCD
camera. These include for instance monitoring of circulating
cells such as stem cells or immune cells, and the measurement
of systemic responses such as the immune or stress responses.
The multiplex reporter system described here provides a
Figure 2. Triple secreted reporter system in culture. U87-Gluc, U87R1-Vluc, and U87R2-SEAP/Fluc cells (singleplex) or a combination of all three
cell lines (multiplex) were plated in a 96-well plate and treated with either TMZ (100 μM) or DMSO control. At diﬀerent time points, aliquots of
conditioned medium were assayed for Gluc, Vluc, or SEAP reporters. Only U87 parental cells responded to TMZ (as observed by Gluc assay) but
not U87R1 or U87R2 cells using both the singleplex and multiplex assay. Data presented as average RLU ± SD (n = 5). Typical background signal
from nontransduced cells for Gluc 0.15 ± 0.012, Vluc 57.61 ± 2.98, and SEAP 7.91 ± 0.83.
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simple, noninvasive, and sensitive method for dynamic analysis
of cell viability both in vitro and ex vivo complementing in vivo
bioluminescence imaging which has the unique ability to
localize the signal, and thereby greatly facilitating noninvasive
monitoring of biological processes.
■ CONCLUSION
In summary, we have developed a multiplexed blood reporter
system for simultaneous monitoring of multiple biological
parameters in the same experimental animal in real time. This
system could be applied in many diﬀerent ﬁelds facilitating the
understanding of disease development and expedites ﬁndings of
novel therapeutics and translation into the clinic.
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